Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04686877Recruiting
Surgery to remove deep brain bleeding with urokinase
This trial tests whether a targeted (stereotactic) procedure to remove deep brain bleeding, combined with a medicine called urokinase, is safer and works better than standard care. It focuses on people whose bleeding is in the deep brain and who are able to undergo surgery within a specific time window.
Fuzhou, FujianAges 40 years+ - NCT07409103RecruitingPhase 2
Testing ELV001 for active rheumatoid arthritis
This study tests a new medication, ELV001, for people with active rheumatoid arthritis who haven't improved enough with methotrexate and a TNF inhibitor. The goal is to see if different doses of ELV001 are safe and can help reduce joint pain and swelling.
Gilbert, ArizonaAges 18–75 - NCT07413094RecruitingPhase 2
Testing a new drug for sepsis-related lung injury
This trial tests a new medicine called YD0743 for people who have both sepsis (a serious infection) and ARDS (a severe lung injury from the infection). The goal is to see if the medicine helps improve breathing and survival.
BeijingAges 18–75 - NCT07408024RecruitingPhase 2
TollB-001 tablets for moderate to severe rheumatoid arthritis
This trial tests an experimental tablet, TollB-001, for people with moderate to severe rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–70 - NCT07412470RecruitingPhase 2/Phase 3
Testing frexalimab vs tacrolimus for new kidney transplant patients
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
San Francisco, CaliforniaAges 18–70 - NCT07414342Recruiting
Study of RENATUS® valve for severe aortic stenosis
This study tests a new device called the RENATUS® Transcatheter Aortic Valve System for people with severe aortic stenosis. It is designed to replace the narrowed valve without open-heart surgery, and aims to see if it is safe and effective for patients with various surgical risk levels.
BeijingAges 60–100 - NCT07410169RecruitingPhase 2/Phase 3
Oxygen therapy for chemo-related nerve pain in breast cancer
This trial tests if hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) can reduce nerve pain caused by the chemotherapy drug nab-paclitaxel in breast cancer patients. It may help women who have finished chemo and are still dealing with numbness, tingling, or pain in their hands or feet.
Guangzhou, GuangdongAges 18–75 - NCT07410364Recruiting
CAG and PCI via distal wrist access for small vessels
This trial tests whether a new wrist access point (the distal radial artery) along with specific drug treatments (CAG and PCI) is safe and effective for people with small blood vessels in the heart. It aims to offer an alternative that may reduce bleeding or damage risks.
Changzhou, JiangsuAges 18–85 - NCT07414225Recruiting
MitraClip procedure for atrial functional mitral regurgitation
This trial tests a minimally invasive procedure to repair a leaky mitral valve in people with a specific type of heart failure. The goal is to see if the procedure, called transcatheter edge-to-edge repair (TEER), is safe and effective in reducing symptoms and improving heart function.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07413835Recruiting
Study of HN2302 for hard-to-treat myasthenia gravis
This trial tests a new medicine called HN2302 for people with generalized myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if HN2302 is safe and helps reduce muscle weakness symptoms.
Xuzhou, JiangsuAges 18–80 - NCT06082050RecruitingEarly Phase 1
YOLT-201 for transthyretin heart disease
This trial tests a new intravenous medicine called YOLT-201 for people with a heart condition caused by buildup of a protein called transthyretin (ATTR-CM). The goal is to see if it can slow or improve the disease.
Hangzhou, ZhejiangAges 18–80 - NCT06771063RecruitingPhase 2
Testing a new pill for vaginal yeast infections
This study tests a new oral medication called WXSH0102 for treating vaginal yeast infections (VVC). It aims to see if the drug is safe and effective for women with active symptoms.
Beijing, Beijing MunicipalityAges 18–64 - NCT07405801RecruitingPhase 2
Inavolisib plus ribociclib plus fulvestrant for advanced breast cancer
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
Anaheim, CaliforniaAges 18 years+ - NCT07400965RecruitingPhase 2
Testing a new eye drop for eyelid inflammation caused by tiny mites
This trial tests an investigational eye drop (GLK-321) to see if it safely and effectively treats Demodex blepharitis, an eyelid inflammation caused by tiny mites. It may help people who have signs of this condition and good enough vision.
Newport Beach, CaliforniaAges 18 years+ - NCT07406152Recruiting
A gel for hard-to-heal chronic wounds
This study tests a new gel and applicator for chronic wounds that are hard to heal, like bed sores, diabetic foot ulcers, and leg ulcers. The goal is to see if the gel helps wounds heal safely.
Vitoria-Gasteiz, ÁlavaAges 18 years+ - NCT07400952RecruitingPhase 2
Testing GLK-221 Eye Drops for Keratoconus
This study tests an eye drop called GLK-221 for people with keratoconus, a condition where the clear front of the eye bulges. The goal is to see if the drops can safely help improve the condition compared to a placebo (an inactive solution).
Westerville, OhioAges 18–55 - NCT07399054Recruiting
Acid-reducing medicine for ICU patients after surgery
This trial tests a medicine called esomeprazole, given through an IV, to see if it safely prevents stomach bleeding in patients who are in the ICU after surgery. If you qualify, you might get this medicine to help protect your stomach while you recover.
Hyderabad, TelanganaAges 18–75 - NCT07399769RecruitingPhase 1/Phase 2
MSLN CAR-T therapy for advanced solid tumors
This trial tests a new immune cell therapy called MSLN CAR-T for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help if your cancer has not responded to standard treatment and tests positive for a protein called mesothelin (MSLN).
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07398872Enrolling by invitationPhase 1
Gene therapy trial for children with ML4
This trial tests a gene therapy given by a one-time injection into the spinal fluid for children with Mucolipidosis type IV. It aims to see if the therapy is safe and can help slow or stop the disease.
Hangzhou, ZhejiangAges 1.5 years–8 years - NCT07406945Recruiting
Testing a new tool during POEM for swallowing problems
This trial tests a new tool (SpydrBlade) during a procedure called POEM to help people with swallowing problems like achalasia. The goal is to see if it's safe and works well.
GuayaquilAges 18 years+ - NCT07406932Recruiting
JAK inhibitors vs standard therapy for lung scarring in Anti-Synthetase Syndrome
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
Beijing, Beijing MunicipalityAges 18–75 - NCT07401537RecruitingPhase 2
Comparing two schedules of immunotherapy for advanced triple-negative breast cancer
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Guangzhou, GuangdongAges 18–70 - NCT07405216RecruitingPhase 4
SGLT2 inhibitors for teens with early kidney disease
This trial tests whether a type of medicine called SGLT2 inhibitors can help teenagers with early-stage chronic kidney disease. It looks at how safe and effective these drugs are for slowing down kidney damage.
Aguascalientes, AguascalientesAges 14–18 - NCT06826872RecruitingPhase 2
Testing SPC1001 for essential hypertension
This trial tests an oral medication called SPC1001 to see if it can safely lower blood pressure in people with essential hypertension (high blood pressure not caused by another condition). It may help if you have mild to moderate high blood pressure.
SeoulAges 19–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.